Stock EIGR EIGER BIOPHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Eiger BioPharmaceuticals, Inc.

Equities

EIGR

US28249U2042

Market Closed - OTC Markets
Other stock markets
 20:33:50 03/05/2024 BST 		5-day change 1st Jan Change
2.69 USD +12.08% Intraday chart for Eiger BioPharmaceuticals, Inc. +0.75% -60.06%
04-24 Motion for Asset Sale Approved for Eiger BioPharmaceuticals, Inc. CI
04-19 Selection of Successful Bidder Filed by Eiger BioPharmaceuticals, Inc. CI

Evolution of the average Target Price on Eiger BioPharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

467ae48a2e03fb9b64ab794b32e.uvc705OUPs_q5UjvdQlYbbBBsPqdoXPSPF0WaPnFFdw.z7Jv5Or1d76fuiWaJmMdNYQW-KjlmCC3bG0iGJC_Roboh1WWw6Zwiq-rJw~85dc68d57d9b18bd5e2d0cbcad2e58a8

Analyst Recommendations on Eiger BioPharmaceuticals, Inc.

News Highlights : Top Company News of the Day - Monday at 11 PM ET DJ
News Highlights : Top Company News of the Day - Monday at 7 PM ET DJ
Citigroup Adjusts Eiger BioPharmaceuticals Price Target to $3 From $4, Maintains Buy Rating MT
Baird Adjusts Price Target on Eiger BioPharmaceuticals to $5 From $3, Maintains Outperform Rating MT
BTIG Adjusts Eiger BioPharmaceuticals' Price Target to $48 from $57, Maintains Buy Rating MT
EIGER BIOPHARMACEUTICALS : Wedbush Suspended Coverage on Eiger BioPharmaceuticals MT
EIGER BIOPHARMACEUTICALS : Citigroup Adjusts Price Target on Eiger BioPharmaceuticals to $26 From $23, Maintains Buy Rating MT
EIGER BIOPHARMACEUTICALS : Wedbush Lifts Price Target for Eiger BioPharmaceuticals to $23 From $22, Maintains Outperform Rating MT
EIGER BIOPHARMACEUTICALS : Wedbush Adjusts Price Target for Eiger BioPharmaceuticals to $22 From $31, Maintains Outperform Rating MT
EIGER BIOPHARMACEUTICALS : Wedbush Adjusts Price Target on Eiger BioPharmaceuticals to $31 From $32, Keeps Outperform Rating MT
Eiger BioPharmaceuticals, Inc. Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to 'All-Oral' Lonafarnib-Ritonavir Regimen in Low Viral Load Hdv-Infected Patients At the International Liver Congress 2018 CI
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.69 USD
Average target price
30 USD
Spread / Average Target
+1,015.24%
High Price Target
30 USD
Spread / Highest target
+1,015.24%
Low Price Target
30 USD
Spread / Lowest Target
+1,015.24%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Eiger BioPharmaceuticals, Inc.

Citigroup
Baird
BTIG
Wedbush

Ratings for Eiger BioPharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. EIGR Stock
  4. Consensus Eiger BioPharmaceuticals, Inc.